Biktarvy’s success raises doubts about ViiV’s ‘new era’ of HIV treatment

[From BioPharmaDive]

“GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company’s first doublet has performed modestly on the market compared to a key rival’s three-drug regimen.”

For more, click here.

Leave a Comment

Scroll to Top